What Helix BioPharma does

Helix BioPharma Corp. is a clinical-stage oncology company developing a proprietary pipeline of bio-conjugate drug candidates that target Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6), a cell-surface protein overexpressed in hard-to-treat solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. The portfolio comprises L-DOS47 (Tumor Defence Breaker), a first-in-class antibody-enzyme conjugate (AEC) that delivers an enzymatic payload to neutralize tumor-microenvironment acidity and convert immunologically "cold" tumors "hot" (Phase Ib completed, Phase II planned in combination with pembrolizumab); LEUMUNA, an oral immune checkpoint modulator targeting purine nucleoside phosphorylase for graft-versus-leukemia effect in post-transplant leukemia relapse (US FDA Orphan Drug Designation, patent through 2041); and GEMCEDA, a first-in-class oral prodrug of gemcitabine combined with cedazuridine achieving approximately 90% bioavailability versus 10% for conventional oral gemcitabine. Discovery-stage CEACAM6-targeting bi-specific antibody-drug conjugates (ADCs) and radionuclide drug conjugates (RDCs) extend the platform into gastrointestinal, gynecological, and other solid tumors.

The company is pre-revenue, with no commercial products, and funds operations through equity private placements and convertible debentures; cash stood at C$2,842,000 as of April 30, 2026, up from C$65,000 as of July 31, 2025. The lead product L-DOS47 generated a 75% overall response rate in its Phase Ib NSCLC study, and preclinical combination with pembrolizumab yielded 70% greater tumor volume reduction versus pembrolizumab alone. Distribution currently flows through clinical trial sites (including Poland via a wholly-owned subsidiary), with planned transition to pharmaceutical wholesalers and specialty pharmacies upon regulatory approval.

Helix BioPharma is publicly listed on the TSX (HBP), OTC PINK (HBPCD), and FWB Frankfurt (HBP0), is headquartered in Vancouver, BC (relocating from Toronto), and is preparing for a Nasdaq uplisting under the Multijurisdictional Disclosure System (MJDS) framework. Customers are healthcare providers and oncology treatment centers serving patients with hard-to-treat solid tumors and post-transplant leukemia relapse; pricing has not been disclosed as no product is commercialized. Composition-of-matter patent coverage extends through 2036 (L-DOS47), 2041 (LEUMUNA), and 2043 (GEMCEDA), with key leadership drawn from multinational pharma including Mundipharma, Bristol-Myers Squibb, and EMD Serono.

Name

Helix BioPharma

Legal name

Helix BioPharma Corp.

Website

https://helixbiopharma.com

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

Helix BioPharma Corp. is a clinical-stage, pre-revenue oncology company developing proprietary CEACAM6-targeting bio-conjugate drug candidates—L-DOS47, LEUMUNA, and GEMCEDA—for hard-to-treat solid tumors and post-transplant leukemia relapse, publicly listed on TSX (HBP) and preparing for a Nasdaq uplisting.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Translational Medicine & Biomarkers (HLAIALAF)

akta.pro secondary industries

Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Clinical-stage oncology
• Antibody-enzyme conjugates
• Immuno-oncology therapeutics
• Tumor microenvironment modulation
• Biopharmaceutical drug development

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Pre-revenue / Clinical-stage development: Helix BioPharma is a pre-revenue clinical-stage company. The company is focused on developing its pipeline of oncology drug candidates through clinical trials. Revenue generation is contingent on successful clinical development, regulatory approval, and commercialization of its pipeline products.
2. Private placement financing: The company raises capital through private placement equity and convertible debenture financings to fund ongoing R&D operations and clinical development programs.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Helix BioPharma is a clinical-stage oncology biopharmaceutical company developing a proprietary pipeline of bio-conjugate drug candidates targeting CEACAM6-overexpressing solid tumors. Its lead asset L-DOS47 is a first-in-class antibody-enzyme conjugate for non-small cell lung cancer; LEUMUNA is an oral immune checkpoint modulator for post-transplant leukemia relapse; and GEMCEDA is an oral gemcitabine prodrug enabling at-home chemotherapy administration.

Product overview

Helix BioPharma is a clinical-stage oncology company with a proprietary platform of bio-conjugates targeting CEACAM6-expressing solid tumors. The company's portfolio consists of lead candidate L-DOS47 (Tumor Defence Breaker), a clinical-stage antibody-enzyme conjugate that normalizes tumor microenvironment acidity to enhance immunotherapy efficacy; LEUMUNA, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse; and GEMCEDA, a pre-IND oral gemcitabine prodrug enabling convenient at-home dosing. The company is also advancing discovery-stage bi-specific ADCs and radionuclide drug conjugates leveraging the same CEACAM6-targeting foundation.

Differentiator

Problem solved

Functional benefit

Brands

• L-DOS47: First-in-class clinical-stage antibody-enzyme conjugate (AEC) that modifies the tumor microenvironment of solid tumors, taking the brakes off the immune system's anti-tumour defences. Also known as Tumour Defence Breaker™.
• LEUMUNA™
• GEMCEDA™

Products and services

• L-DOS47 (Tumour Defence Breaker) First-in-class clinical-stage antibody-enzyme conjugate (AEC) that targets CEACAM6-overexpressing solid tumors and delivers a urease payload to neutralize tumor microenvironment acidity, restoring immune cell infiltration and enhancing checkpoint inhibitor efficacy in NSCLC and other hard-to-treat solid tumors. Composition-of-matter patent coverage through 2036.
• LEUMUNA (ulodesine hemiglutarate) Oral immune checkpoint modulator that inhibits purine nucleoside phosphorylase (PNP) to activate the donor immune system and induce a graft-versus-leukemia (GvL) effect in patients experiencing leukemia relapse after allogeneic stem cell transplantation. Holds FDA Orphan Drug Designation and patent protection through 2041.
• GEMCEDA First-in-class oral prodrug of gemcitabine combined with cedazuridine (a dehydrogenase inhibitor) that enables convenient at-home oral administration with approximately 90% bioavailability versus 10% for conventional oral gemcitabine, supporting metronomic dosing and combination with checkpoint inhibitors. Patent coverage through 2043.

Quantifiable outcome

• 75% overall response rate in Phase Ib NSCLC study with L-DOS47 + chemotherapy (pemetrexed/carboplatin), including one near-complete remission in heavily pre-treated Stage IV patients
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• MetaShape PharmaminorOEM/ Whitelabel/ Licensing Partner · 1 May 2026Helix BioPharma licensed MS 001 (a development program based on the same PNP inhibition platform as LEUMUNA) to MetaShape Pharma for exploration in obesity and potentially neurodegenerative disease. MS 001 is being developed separately from Helix's LEUMUNA program which focuses on post-transplant leukemia relapse.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Bolt Biotherapeutics: Bolt Biotherapeutics is a clinical-stage oncology company developing immune-stimulating antibody conjugates (ISACs) that, like Helix's L-DOS47, target the tumor microenvironment and aim to convert cold tumors hot when combined with checkpoint inhibitors. Both companies share a bio-conjugate platform modality with first-in-class mechanisms for solid tumors.
• CytomX Therapeutics: CytomX develops masked, protease-activated antibody conjugates (Probodies) for oncology, a bio-conjugate approach with similar novel mechanism-of-action flavor to Helix's antibody-enzyme conjugates targeting CEACAM6. Both are clinical-stage and target tumor selectivity / TME modulation as core differentiators.
• Pyxis Oncology: Pyxis Oncology is a clinical-stage biopharmaceutical company developing antibody-drug conjugates including bi-specific ADCs against cancer targets in solid tumors, directly overlapping with Helix's discovery-stage CEACAM6 bi-specific ADC program. Both companies pursue next-generation ADC design to address hard-to-treat tumors.
• Mersana Therapeutics: Mersana Therapeutics is a clinical-stage oncology company developing novel ADCs with proprietary conjugation platforms (Dolasynthen, ImmunoLynx) targeting solid tumors, comparable to Helix's CEACAM6 bio-conjugate platform and ADC pipeline. Both companies compete for oncology partnership/licensing dollars.
• Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptide-based conjugates (Bicycles) for oncology including tumor-targeted toxins and T-cell engagers, representing an alternative novel bio-conjugate modality with similar first-in-class positioning to Helix's antibody-enzyme conjugates. Both pursue differentiated chemistries against validated oncology targets.
• Tubulis: Tubulis is a clinical-stage ADC developer focused on novel conjugation chemistries (P5 conjugation technology) and stable linkers for solid tumor ADCs, making it a direct peer to Helix's bi-specific ADC discovery program. Both innovate at the conjugation and linker chemistry layer of antibody-drug conjugates.
• Marker Therapeutics: Marker Therapeutics is a clinical-stage cell therapy company developing MultiTAA-specific T cells for post-transplant leukemia relapse, directly comparable to LEUMUNA's graft-versus-leukemia (GvL) induction approach in post-allo-SCT leukemia. Both target the same orphan indication with novel immunologic strategies.

Broad incumbents

• ImmunoGen: ImmunoGen, recently acquired by AbbVie for approximately $10.1B, is a pioneer in ADC technology including FDA-approved Elahere. As an established incumbent with broader oncology pipeline and resources, it provides a benchmark for the kind of ADC-platform exit Helix could pursue.

Emerging players

• Actinium Pharmaceuticals: Actinium Pharmaceuticals is a clinical-stage oncology company developing targeted radiopharmaceuticals (Iomab-B, Actimab) including for AML and conditioning before transplant, addressing similar hematology/transplant indications as LEUMUNA. Both target niche oncology indications where no approved standard exists.
• PharmaCyte Biotech: PharmaCyte Biotech develops encapsulated cell therapies combining prodrug-activation with tumor-targeted delivery, conceptually similar to Helix's tumor-microenvironment-modulating approach (L-DOS47 raises TME pH; PharmaCyte activates chemotherapy in tumor). Both pursue novel localized oncology mechanisms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/H3lixBioPharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Helix BioPharma